ArticleSurgical endoscopy2026
Pilot study of EsoCheck/EsoGuard for detecting Barrett's esophagus in high-risk patients undergoing hiatal hernia repair.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal adenocarcinoma (EAC) has poor survival outcomes, yet population-level screening remains limited. EsoCheck, a swallowable balloon device paired with the EsoGuard DNA methylation assay, is a minimally invasive screening tool for Barrett's esophagus (BE), a precursor to EAC. Hiatal hernia is a strong risk factor for BE. This pilot study provides preliminary insight into the diagnostic performance of intraoperative EsoCheck/EsoGuard compared with upper endoscopic biopsies for screening patients undergoing hiatal hernia repair.
methodsThis prospective cross-sectional study was conducted at a single institution. Eligible participants were aged ≥ 18, had a diagnosis of GERD, and were undergoing BE screening or surveillance followed by planned hiatal hernia repair. Exclusion criteria included a history of esophageal malignancy or surgery. Patients were placed under general anesthesia for sample collection, followed by hiatal hernia repair. Distal esophageal samples collected via EsoCheck and upper endoscopy were analyzed by the EsoGuard assay and histopathology, respectively.
results28 patients underwent successful sample collection and hernia repair. Mean BMI was 28.6 ± 6.2 and mean age was 56.9 ± 14.9 years. Patients were 71% women, 79% White, 36% obese, and 39% had a history of smoking. Mean number of risk factors per patient based on ACG guidelines was 3.5 ± 1.1. BE was detected in 6 (21%) patients, with 3 being short-segment BE (< 3 cm). EsoGuard showed sensitivity of 83.3% (95% CI 35.9-99.6) and specificity of 63.6% (95% CI 40.7-82.8). Positive predictive value was 38.5% (95% CI 24.4-54.7) and negative predictive value was 93.3% (95% CI 69.5-98.9). Of the 8 patients with false-positive EsoGuard results, 5 had chronic inflammatory mucosal changes on pathology. No complications were associated with EsoCheck sampling.
conclusionsEsoCheck/EsoGuard demonstrates high sensitivity and meets the criteria for a screening tool for BE. Given its low specificity, positive results mandate a confirmatory test, such as upper endoscopy with biopsies.
Indexed as
Identifiers
42377511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.